Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA)
The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.
Abstract
This review summarizes the evidence for a hypertensinogenic effect of Erythropoietin (Epo) in normal human subjects and predialysis, hemodialysis, and continuous ambulatory peritoneal dialysis (CAPD) patients. The possible mechanisms of Epo-induced hypertension are examined with in vivo animal and in vitro data, as well as pathophysiological human studies in both normal subjects and CKD patients. The evidence for a hypertensinogenic effect of erythropoiesis-stimulating agents (ESAs) in normal subjects, predialysis CKD, hemodialysis, and CAPD patients is compelling. Epo increases BP directly and notably independently of its erythropoietic effect and its effect on blood rheology. The potential for the development of future agents that might act as specific stimulators of erythropoiesis, devoid of direct hemodynamic side effects is underscored.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NSAIDs can antagonize the effects of RAAS-inhibitors and beta blockers”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
In the citing paper
“No increase in blood pressure with aspirin”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
In the citing paper
“3/1 mm Hg increase with nonselective NSAIDs”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
In the citing paper
“No difference or an increase of up to 3/1 mm Hg with celecoxib”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
In the citing paper
“Increased odds ratio of 3.19 of hypertension with tricyclic antidepressant”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762 · cited 9×
“Epo treatment showed a trend to an increased risk for hypertensive AEs by 26% as compared with no Epo/placebo, but the effect was not statistically significant.”
BackgroundInfluentialNormalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K.-U., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,104 · cited 10×
“Epo treatment showed a trend to an increased risk for hypertensive AEs by 26% as compared with no Epo/placebo, but the effect was not statistically significant.”
BackgroundInfluentialEschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795 · cited 1×
“magnitude of the Epo-induced increase in BP (32).”
BackgroundStroke risk profile: adjustment for antihypertensive medication. The Framingham Study.
D'Agostino, R. B., Wolf, P. A., Belanger, A. J., & Kannel, W. B. (1994) · Stroke · doi:10.1161/01.str.25.1.40 · Cited by 712
Phrommintikul, A., Haas, S. J., Elsik, M., & Krum, H. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60194-9 · Cited by 638 · cited 1×
“Recently, another meta-analysis (24) reported the hypertension AEs in controlled trials that targeted high versus low blood Hb values and included trials previously included in a metaanalysis (21).”
BackgroundSecondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes
Szczech, L. A., Barnhart, H. X., Inrig, J. K., Reddan, D. N., Sapp, S., Califf, R. M., Patel, U. D., & Singh, A. K. (2008) · Kidney International · doi:10.1038/ki.2008.295 · Cited by 526
Parfrey, P. S., Foley, R. N., Wittreich, B. H., Sullivan, D. J., Zagari, M. J., & Frei, D. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004121039 · Cited by 373 · cited 2×
“One Hb target-controlled trial (41) did not find”
BackgroundHealth centres of today; Finsbury, Peckham.
STEWART, A. B., & Williamson, G. S. (1946) · PubMed · Cited by 256
Revicki, D. A., Brown, R. E., Feeny, D. H., Henry, D., Teehan, B. P., Rudnick, M. R., & Benz, R. L. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90122-1 · Cited by 254 · cited 1×
“96) Revicki 1995 (91) Predialysis 4/40 11/43 16.”
Casati, S., Passerini, P., Campise, M. R., Graziani, G., Cesana, B., Perisic, M., & Ponticelli, C. (1987) · BMJ · doi:10.1136/bmj.295.6605.1017 · Cited by 242
Cited by
Items 101–181 of 181
Masked uncontrolled hypertension in patients on maintenance hemodialysis
Liu, W., Wang, L., Sun, Z., Li, X., Zhou, J., Gao, C., Chu, H., Fan, W., Bai, Y., & Yang, J. (2017) · Hypertension Research · doi:10.1038/hr.2017.48 · Cited by 9
Sun, P., Kumar, N., Tin, A., Zhao, J., Brown, M. R., Lin, Z., Yang, M.-L., Zheng, Q., Jia, J., Bielak, L. F., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17597 · Cited by 9
Günter, C. I., Ilg, F. P., Hapfelmeier, A., Egert-Schwender, S., JELKMANN, W. E. B., Giri, S., Bader, A., Machens, H.-G., & and EPO in Burns Study Group (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.812888 · Cited by 9
Yazaki, M., Nabeta, T., Takigami, Y., Eda, Y., Fujita, T., Iida, Y., Ikeda, Y., Ishii, S., & Ako, J. (2024) · Medicina · doi:10.3390/medicina60010084 · Cited by 9
“Increasing peripheral vascular resistance by reducing blood viscosity and reducing hypoxic vasodilation is the main mechanism for increasing blood pressure with erythropoiesis-stimulating agent treatment [21,22].”
BackgroundInterdialytic Hypertension—An Update
Agarwal, R. (2011) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2010.10.001 · Cited by 11
Hepatic erythropoietin response in cirrhosis. A contemporary review
Risør, L. M., Fenger, M., Olsen, N. V., & Møller, S. (2016) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2016.1143563 · Cited by 9
“ET-1-induced renal NO production has been shown to inhibit collecting duct sodium and water reabsorption in sufficient magnitude to lower blood pressure in mice, implying a potential counter-regulatory mechanism against EPO-induced hypertension [33].”
BackgroundOhki, K., Wakui, H., Uneda, K., Azushima, K., Haruhara, K., Kinguchi, S., Urate, S., Yamada, T., Yamaji, T., Kobayashi, R., et al. (2020) · Kidney Diseases · doi:10.1159/000507396 · Cited by 9
Armstrong, N. D., Srinivasasainagendra, V., Chekka, L. M. S., Nguyen, N., Nahid, N. A., Jones, A. C., Tanner, R. M., Hidalgo, B., Limdi, N. A., Claas, S. A., et al. (2022) · Genes · doi:10.3390/genes13071260 · Cited by 7
“Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization [42] and are involved in several physiological processes including vascular and smooth muscle contraction, which is important in BP regulation [48,49].”
BackgroundHypertension in children with end-stage renal disease
Roszkowska–Blaim, M., & Skrzypczyk, P. (2015) · Advances in Medical Sciences · doi:10.1016/j.advms.2015.07.001 · Cited by 7
Schmid, H. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2016.1112734 · Cited by 7
“[91] In patients with CKD under MPG-EPO treatment, intensification of antihypertensive therapy was required in >25% of patients due to impairment of both endothelium-dependent as well as endothelium-independent vasodilation.[92] Of note, the odds ratio of hypertension compared to placebo is generally increased under t…”
BackgroundSpecial Problems in Hemodialysis Patients
Penido, M. G. M. G. (2011) · InTech eBooks · doi:10.5772/1840 · Cited by 8
Rao, A., Pitcher, D., & Farrington, K. (2013) · Nephron Clinical Practice · doi:10.1159/000360030 · Cited by 6
Hypertension in the Hemodialysis Patient
Hommos, M. S., & Schinstock, C. A. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_88 · Cited by 6
Hirai, T., Nishizawa, Y., Nakazono, H., Asai, M., Yamashita, H., Sasaki, A., Yamashita, T., Yamashita, K., Shigemoto, K., Harada, S., et al. (2013) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12013 · Cited by 6
Vankar, S., Dutta, P. R., Kohli, H. S., & Bhansali, A. K. (2014) · PubMed Central · Cited by 5
Ribeiro, S., Garrido, P., Fernandes, J. C., Vala, H., Rocha‐Pereira, P., Costa, E. M., Belo, L., Reis, F., & Santos‐Silva, A. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.02.088 · Cited by 5
Hida, Y., Imamura, T., & Kinugawa, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247619 · Cited by 5
“Although the mechanism behind these findings remains unclear, it is suggested that anemia correction may increase vascular resistance and afterload on the left ventricle by raising blood viscosity and diminishing hypoxic vasodilation [23].”
Blood pressure increase after erythropoietin injection in hemodialysis and predialysis patients.
Noshad, H. (2013) · Iranian Journal of Kidney Diseases · Cited by 5
Aachmann‐Andersen, N. J., Christensen, S. J., Lisbjerg, K., Oturai, P., Johansson, P. I., Holstein‐Rathlou, N., & Olsen, N. V. (2018) · Physiological Reports · doi:10.14814/phy2.13573 · Cited by 5
Vitamin C and functional iron deficiency anemia in hemodialysis
Kim, Y.-L. (2012) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2011.12.008 · Cited by 5
Wrobeln, A., Schäper, T. M., Schild, Y., Kleine-Möllhoff, L., Leu, T., Jägers, J., Budeus, B., Heinrich, A., Sperber, H. S., Schwarzer, R., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf167 · Cited by 4
Ribeiro, S., Costa, E. M., Belo, L., Reis, F., & Santos‐Silva, A. (2013) · InTech eBooks · doi:10.5772/52061 · Cited by 8
Hypertension Treatment for Patients with Advanced Chronic Kidney Disease
Sinha, A. D., & Agarwal, R. (2014) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-014-0400-y · Cited by 5
“While over the counter nonsteroidal anti-inflammatory drugs and decongestants can exacerbate hypertension, erythropoiesis stimulating agents are commonly prescribed for the anemia of CKD and resultant hypertension has been reported in up to 30% of patients [17].”
BackgroundVestergaard, M. B., Henriksen, O. M., Lindberg, U., Aachmann‐Andersen, N. J., Lisbjerg, K., Christensen, S. J., Olsen, N. V., Law, I. G., Larsson, H. B. W., & Rasmussen, P. V. (2018) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00869.2017 · Cited by 4
“Prior studies have shown a minor increase in blood pressure; however, these effects are after long-term EPO treatment and only measureable with invasive blood pressure monitoring (19, 20).”
BackgroundWu, C., Tsai, Y., Jung, H.-K., Fu, S., Hsiung, C. A., Liu, H., & Lai, J. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1965 · Cited by 5
Roy, M., Saroha, S., Sarma, U., Sarathy, H., & Kumar, R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274490 · Cited by 3
Erythropoietin Stimulation and Other Blood Doping Methods
Rhee, J. W., & Erickson, T. B. (2012) · Wiley eBooks · doi:10.1002/9781118105955.ch17 · Cited by 4
Erythropoietin Improves Cardiovascular Function in Adult Rats After Acute Hemorrhage
Puchulu, M. B., Arreche, N., Zotta, E., Donato, M., Ogonowski, N. S., Fellet, A. L., & Balaszczuk, A. M. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000666 · Cited by 3
Licht-Ardila, M., Romero, L. A., & Vallejo-Ardila, D. L. (2022) · Revista Colombiana de Cardiología · doi:10.24875/rccar.21000078 · Cited by 7
Moura, A. F., Moitinho, J. A. O., Luz, L. G. D., Suassuna, J. H. R., & Moura-Neto, J. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-44557-6_6 · Cited by 4
Hematologic and Infectious Complications of Chronic Kidney Disease
Lakkis, J. I., & Weir, M. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00031-0 · Cited by 5
Therapeutic effect of erythropoietin and its derivatives in the treatment of acute ischemic stroke
Rama, R., & Torrella, J. R. (2025) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2025.1004101 · Cited by 2
Zhang, A., Nakano, D., Morisawa, N., Kitada, K., Kittikulsuth, W., Rahman, A., Morikawa, T., Konishi, Y., & Nishiyama, A. (2021) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.03.007 · Cited by 2
Rivera, M. G. U., Obrador-Mulet, A., Mendoza, S. C. J., Corral-Baez, A., Periañez-Párraga, L., Álvarez, Á. G., & la Prada, F. J. D. (2021) · Journal of Hematology · doi:10.14740/jh862 · Cited by 2
“While this finding does not have a straight forward explanation, it might be related to a direct hypertensinogenic effect of a higher number of drug administrations in this arm of treatment [38].”
BackgroundShimamoto, Y., Sasaki, H., Kasuno, K., Watanabe, Y., Sakashita, S., Nishikawa, S., Nishimori, K., Morita, S., Nishikawa, Y., Kobayashi, M., et al. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03319-7 · Cited by 2
“Endocrinological changes, such as enhanced noradrenergic and angiotensin II sensitivity and endothelin-1 concentration, have also been suggested to play a role [20].”
Hypertension and Chronic Kidney Disease Including Dialysis
Dhaybi, O. A., & Bakris, G. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00035-9 · Cited by 2
Naturally nonanemic dialysis patients: Who are they?
Yılmaz, M., Kırçelli, F., Artan, A. S., Oto, Ö. A., Aşçı, G., Güneştepe, K., Başçı, A., Ok, E., & Sever, M. Ş. (2016) · Hemodialysis International · doi:10.1111/hdi.12425 · Cited by 2
Hypertension artérielle d'origine médicamenteuse et toxique
Marié, I. (2010) · EMC - Cardiologie · doi:10.1016/s1166-4568(10)45116-5 · Cited by 2
“Depuis, d’autres études ont relevé la survenue d’une hypertension artérielle ou l’aggravation d’une hypertension artérielle préexistante sous érythropoïétine chez environ un tiers des patients en hémodialyse [21-29].”
Behandlung von Hunden und Katzen mit systemischer Hypertension aufgrund von Nierenerkrankungen
Buoncompagni, S., & Bowles, M. H. (2014) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.1055/s-0038-1623763 · Cited by 2
“So ist es wichtig, jegliche Medikation des Patienten zu überprüfen, die eine Blutdrucksteigerung bewirken kann, wie beispielsweise Kortikosteroide, Phenylpropanolamin, nichtsteroidale Antiphlogistika (11) und Erythropoetin (13).”
BackgroundFranczyk, B., Gluba-Brzózka, A., Banach, M., & Rysz, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-56827-0_2 · Cited by 2
“It has been demonstrated that in hemodialysis patients, angiotensin II infusion during Epo treatment was associated with higher elevation of blood pressure in comparison to pre-Epo condition [41].”
BackgroundResultDrug Utilization Evaluation of Erythropoietin at a Referral Teaching Hospital in Iran
Karimzadeh, I., Rasekh, H., Karimian, A., Shabani-Borujeni, M., & Vazin, A. (2023) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/2023/6685602 · Cited by 1
“Finally, there were no other cases of absolute or partial contraindication of EPO (e.g., pure red cell aplasia and documented hypersensitivity reactions to EPO [31]) in the study population.”
BackgroundThe effect of anemia management on chronic renal failure progression
Ghobrial, E. E., Salama, K. M., Shiba, M. F., & Shafae, N. H. E. (2013) · Egyptian Pediatric Association Gazette · doi:10.1016/j.epag.2013.04.008 · Cited by 1
“Also, Krapf and Hulter (2009),12 reported that rHuEpo-treated patients showed a trend to an increased risk for hypertension by 26% compared with no rHuEpo/placebo, but the effect was not statistically significant.”
BackgroundDrug-Induced Hypertension in Chronic Kidney Disease
Vichot, A. A., & Perazella, M. A. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6436-9_12 · Cited by 1
The Endothelium and Hemodialysis
Trimarchi, H. (2011) · InTech eBooks · doi:10.5772/24192 · Cited by 1
Erythropoietin induced miliaria crystallina: A possible new adverse effect of erythropoietin
Kumar, S., Mahajan, B. B., Kaur, S., & Singh, A. (2014) · International Journal of Case Reports and Images · doi:10.5348/ijcri-2014112-cr-10423 · Cited by 1
“Various factors are thought to contribute to hypertension as exemplified in various studies [5–7].”
BackgroundA Truncated Erythropoietin Receptor EPOR-T Is Associated With Hypertension Susceptibility
Carruthers, S. G. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.119 · Cited by 1
Joré, C., Brun, J. ‐., & Varlet‐Marie, E. (2016) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-168015 · Cited by 1
“Interestingly, effects of EPO on blood pressure are probably not due to its effects on hematocrit, since a rise in blood pressure is observed after EPO even if hematocrit is kept constant [33] and is not correlated to changes in red blood cell mass and viscosity [12].”
The Role of Erythropoietin-Derived Peptides in Tissue Protection
Zhang, C., & Yang, C. (2018) · InTech eBooks · doi:10.5772/intechopen.71931 · Cited by 1
“protective effects, which simultaneously elicits some severe erythropoiesis-related side effects [9].”
BackgroundHypertension and Chronic Kidney Disease
Sternlicht, H., & Bakris, G. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00033-0 · Cited by 1
Jose, M., Singh, S. K., Achankunju, V., Sundaraswamy, P., Sherief, S. H., & Thangaval, S. (2020) · International Journal of Research and Development in Pharmacy and Life Sciences · doi:10.47128/ijrdpl.2278- · Cited by 1
Differences between the Incident and Prevalent Hemodialysis Patients in Egypt
Megahed, A. F., El‐Said, G., Tawfik, M., & Sayed‐Ahmed, N. (2020) · Asian Journal of Medicine and Health · doi:10.9734/ajmah/2020/v18i1130268 · Cited by 1
“Hypertension in CKD and HD patients may develop de novo or may be due to several factors including volume overload, and erythropoietin-use [23,24].”
BackgroundThe Adverse Drug Reactions of Erythropoietin in Chronic Kidney Disease Patients
Mubarokah, I. Z., & Rahmawati, F. (2022) · Atlantis Highlights in Chemistry and Pharmaceutical Sciences/Atlantis highlights in chemistry and pharmaceutical sciences · doi:10.2991/978-94-6463-050-3_8 · Cited by 1
Anemia in children with chronic kidney disease
Park, M. J., & Cho, M. H. (2023) · Journal of the Korean Society of Pediatric Nephrology · doi:10.3339/ckd.23.016 · Cited by 1
“One of the most recognized side effects of ESA is hypertension, which is of particular significance because of its role as both a cardiovascular risk factor and a mediator of kidney disease progression [30,33].”
BackgroundErythropoietin in the Treatment of Anaemia
Ghosh, N., Dey, G., Rakshit, P., & De, S. (2024) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-97-1148-2_13 · Cited by 2
Blood Pressure: Definition, Diagnosis, and Management
Townsend, R. R., & Steigerwalt, S. P. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-010-6_1 · Cited by 1
Klopsch, C., Furlani, D., Gäbel, R., Pittermann, E., Yerebakan, C., Kaminski, A., Ma, N., Liebold, A., & Steinhoff, G. (2010) · Zeitschrift für Herz- Thorax- und Gefäßchirurgie · doi:10.1007/s00398-010-0806-x
Patel, T. V., & Singh, A. K. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3694-2_2
Cerebral blood flow control in small vessel disease
Kim, Y.-S. (2014) · UvA-DARE (University of Amsterdam) · Cited by 1
Erythropoietin Therapy for Heart Failure
Borovka, M., & Maurer, M. S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0268-2_15
Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction—Reply
Najjar, S. S. (2011) · JAMA · doi:10.1001/jama.2011.1145
Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction
Krapf, R. (2011) · JAMA · doi:10.1001/jama.2011.1143
Self-citationBalabanyan, V. Y., Ul’yanov, A. M., Елизарова, О. С., Solev, I. N., Литвинова, С. А., Гарибова, Т. Л., & Воронина, Т. А. (2013) · Russian Journal of General Chemistry · doi:10.1134/s1070363213120566
Duckworth, S. E. (2010) · University Library - University of Saskatchewan (University of Saskatchewan)
Oxide in hemodialysis patients
Dejanova, B., Dejanov, P., Petrovska, S., & Jakovljevic, V. (2011) · Serbian Journal of Experimental and Clinical Research · doi:10.5937/sjecr1102075d
Pathophysiology of Pediatric Hypertension
Yamaguchi, I., & Flynn, J. T. (2015) · Springer eBooks · doi:10.1007/978-3-662-43596-0_55
Hypertension in the Dialysis Patient
Sinha, A. D. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6436-9_7
Proteomic analysis of erythropoietin-induced changes in neuron-like SH-SY5Y cells
Erbayraktar, Z., Önkal, Z., Genç, K. K., & Genç, Ş. (2017) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2016-0310
“EPO has a direct effect on blood pressure [29], which is independent of its hematopoietic effects [16].”
BackgroundOrasan, O. H., Petrov, L., Urian, L. G., Cozma, A., Ciulei, G., Pațiu, I. M., & Orasan, R. A. (2017) · Revista română de medicină de laborator · doi:10.1515/rrlm-2017-0032
“The effect on blood pressure was dose-dependent (16).”
BackgroundIBRAHIM, M. D. A. A. M. M. N., & Fathy, M. (2018) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2018.56751
Erythropoietin in Autonomic Failure
Biaggioni, I. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-386525-0.00135-9
Myocardial Functional Disorders In Hemodialysis Patient With Intradialytic Hypertention
Ibrahim, M., El-Shahawy, E.-M. L., Abdelsalam, H., Mansour, A., & Mohamed, N. F. (2020) · Benha Medical Journal · doi:10.21608/bmfj.2020.109996
“1128 Table (6): Echo parameters pre and post dialysis in patient with intradialytic HTN and non-intradialytic HTN.”
InfluentialAnemia as an adaptive phenomenon
Soeters, P. B., & de Leeuw, P. W. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820205-0.00012-8
The use of epoetin alfa biosimilar in the anemia management in hemodialysis patients
Dudar, І., Krasjuk, E., Honchar, Y., Loboda, O., Shifris, І., Krot, V., & Savchuk, V. (2021) · Ukrainian Journal of Nephrology and Dialysis · doi:10.31450/ukrjnd.3(71).2021.05
“За даними попередніх досліджень гіпертензія, що обумовлюється епоетином, являється найбільш поширеним побічним явищем, констатується у 10-30% гемодіалізних хворих, котрі отримують епоетин, та може мати тяжкий перебіг [10, 11].”
Current awareness: Pharmacoepidemiology and drug safety
(2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1651
Maddux Dugan, W. (2018) · Research Publications (Maastricht University) · doi:10.26481/dis.20181218dm
Blood Pressure: Definition, Diagnosis, and Management
Townsend, R. R., & Steigerwalt, S. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-29152-9_1
Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk
Harlow, C. E., Patel, V. V., Waterworth, D. M., Wood, A. R., Beaumont, R. N., Ruth, K. S., Tyrrell, J., Oguro‐Ando, A., Chu, A. Y., & Frayling, T. M. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac215
Kraft, L., & Latus, J. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21183-6.00003-9
Agarwal, R. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf200
Oncohypertension: Unraveling the Link Between Cancer and Hypertension
Gudsoorkar, P. S., Hanna, P. E., Meena, P., & Karam, S. (2026) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2026.06.002
Metadata
- Authors
- Krapf, R., & Hulter, H. N.
- Affiliations
- University of Basel (CH)
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2009-02
- Volume
- 4
- Issue
- 2
- Pages
- 470-480
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2130991130
- Cited by
- 180
- References
- 88
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 7 · 2022: 10 · 2021: 12 · 2020: 7 · 2019: 11 · 2018: 13 · 2017: 10 · 2016: 14 · 2015: 9 · 2014: 13 · 2013: 15 · 2012: 8
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Keywords
- erythropoietin, erythropoiesis-stimulating agents, hypertension, hemodialysis, continuous ambulatory peritoneal dialysis, chronic kidney disease, blood pressure, hemorheology, erythropoiesis
- MeSH terms
- Anemia, Animals, Arteries, Blood Pressure, Chronic Disease, Erythropoietin, Hematinics, Renal Dialysis, Humans, Hypertension, Kidney Diseases, Peritoneal Dialysis, Continuous Ambulatory, Risk Assessment, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.